Trademarks = 4

Forward Citations = 10

Loading Chart...

4 inventors (with patents filed for the assignee):

Roman Yelensky (3 out of 31 patents)

Brendan Bulik-Sullivan (3 out of 6 patents)

Adnan Derti (3 out of 4 patents)

4. Jennifer Busby (3 out of 5 patents)

3 patents: Sort by Forward Citations

1. 10847253 - Neoantigen identification, manufacture, and use (2020-11-24),

2. 10847252 - Neoantigen identification, manufacture, and use (2020-11-24),

3. 10055540 - Neoantigen identification, manufacture, and use (2018-08-21),

Gritstone Oncology, Inc. is a biotechnology company focused on the development of innovative immunotherapies for cancer treatment. Utilizing its proprietary Gritstone’s EDGE platform, the company aims to discover and develop personalized cancer vaccines and adoptive T cell therapies. Gritstone's pipeline includes programs targeting multiple cancer types, with a strong emphasis on the immune system's role in fighting tumors. The company is committed to unlocking the potential of the immune system to improve patient outcomes through its unique approaches to cancer treatment.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

3 Patents

#95 in Emeryville, CA

#16,408 in California

#71,968 in US

Emeryville, CA, United States of America

Gritstone Oncology, Inc.

Forward Citations = 10

4 inventors:

Roman Yelensky (3 out of 31 patents)

Brendan Bulik-Sullivan (3 out of 6 patents)

Adnan Derti (3 out of 4 patents)

4. Jennifer Busby (3 out of 5 patents)

Please report any incorrect information to support@idiyas.com